Literature DB >> 6859782

The transduodenal per-ampullary approach to common bile duct calculi.

A E Carter.   

Abstract

A method of management of 212 patients whose common bile duct calculi were removed through the Ampulla of Vater across the duodenum is described. One patient died from haemorrhagic pancreatitis directly related to the procedure and 11 others died from causes related to the need for a major procedure in people relatively late in life: an overall mortality of 5.7% and of 0.5% for directly related causes. Ten patients suffered non-fatal complications. Ninety three left hospital within 14 days after operation and 79 within 21 days. Although one patient, for a special reason, continued to form stones and discharged them without any difficulty, no others have formed stones that have been recognised symptomatically or clinically. No patient has had cholangitis or common duct stenosis.

Entities:  

Mesh:

Year:  1983        PMID: 6859782      PMCID: PMC2494297     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  5 in total

1.  Surgery of the biliary tract.

Authors:  R B CATTELL; K W WARREN
Journal:  N Engl J Med       Date:  1956-10-11       Impact factor: 91.245

2.  Kocher's perampullary approach for common bile-duct calculi.

Authors:  A E Carter
Journal:  Br J Surg       Date:  1973-02       Impact factor: 6.939

3.  Sphincterplasty in the treatment of biliary and pancreatic disease.

Authors:  R L Rothwell-Jackson
Journal:  Br J Surg       Date:  1968-08       Impact factor: 6.939

4.  Surgery of the bile ducts.

Authors:  A J Rains
Journal:  Proc R Soc Med       Date:  1969-02

5.  Postcholecystectomy choledocholithiasis.

Authors:  F Glenn
Journal:  Surg Gynecol Obstet       Date:  1972-02
  5 in total
  1 in total

1.  Transduodenal exploration of the common bile duct in a district general hospital.

Authors:  D J Cave-Bigley; P Aukland; J F Kane; E G Hardy
Journal:  Ann R Coll Surg Engl       Date:  1984-05       Impact factor: 1.891

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.